LightDeck Diagnostics Awarded $5.65M to Develop a Covid-19 Rapid Antigen Test
These funds will enable the company to develop a point-of-care antigen test that delivers results in less than 6 minutes.
Read MorePosted by Laurie Bonner | Feb 25, 2021 | Company News, Covid 19, POC Rapid Assays |
These funds will enable the company to develop a point-of-care antigen test that delivers results in less than 6 minutes.
Read MorePosted by Melanie Hamilton-Basich | Feb 24, 2021 | Covid 19 |
The LumiraDx Platform simplifies, scales down, and integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point-of-care instrument.
Read MorePosted by Melanie Hamilton-Basich | Feb 24, 2021 | Covid 19 |
The lateral flow immunoassay test can be used to screen or to aid in diagnoses of covid-19 in asymptomatic or symptomatic individuals.
Read MorePosted by Laurie Bonner | Feb 24, 2021 | Covid 19, Point-of-Care |
Luminostics’ Clip Covid Rapid Antigen Test uses smartphone technology to detect SARS-CoV-2 viral antigens from nasal swabs in around 30 minutes.
Read MorePosted by Melanie Hamilton-Basich | Feb 22, 2021 | Covid 19 |
The test uses AnteoTech’s AnteoBind technology to support significantly improved sensitivity, and is the first covid-19 rapid self-test authorized by the FDA.
Read More